From discovery to delivery: AI’s impact on nanomedicine

Nanomedicine promises precision. The challenge is making that precision repeatable, scalable, and safe.

In this episode of Data in Biotech, Ross Katz speaks with Mitra Mosharraf, Chief Scientific Officer at HTD Biosystems, about how AI and machine learning are changing the way nano-enabled therapies are discovered, formulated, and brought into the clinic.

They dig into:

>> How AI and ML reduce cost and risk across nanomedicine development

>> Why nano drug delivery remains technically challenging and where machine learning helps

>> How predictive modeling accelerates formulation decisions instead of relying on trial-and-error

The conversation highlights a shift away from intuition-driven formulation toward data-informed systems that learn, adapt, and scale without losing scientific rigor.

Listen to the full episode of Data in Biotech:

Apple
Spotify
YouTube

#DataInBiotech #CorrDyn #HTDBiosystems #Nanomedicine #AIinBiotech #PharmaInnovation

‍